|Dr. Waleed H. Hassanein M.D.||Founder, President, CEO & Director||1.46M||2.21M||1968|
|Mr. Stephen Gordon||CFO, Treasurer & Secretary||744.62k||2.55M||1968|
|Dr. Tamer I. Khayal M.D.||Chief Commercial Officer||748.78k||3.15M||1969|
|Ms. Miriam C. Provost Ph.D.||Vice President of Global Regulatory Affairs||535.93k||390.25k||1961|
|Mr. Nick Corcoran||Senior Vice President of Supply Chain & Operations||N/A||N/A||1982|
|Mr. Mark Anderson||Senior Director of Technology Development||N/A||N/A||N/A|
|Mr. Anil Ranganath||Senior VP, General Counsel & Corporate Secretary||N/A||N/A||N/A|
|Ms. Susan Goodman||Vice President of Human Resources||N/A||N/A||N/A|
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc.’s ISS Governance QualityScore as of December 1, 2023 is 3. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 6.